Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Stock Based Compensation

v3.23.1
Stockholders' Equity and Stock Based Compensation
3 Months Ended
Mar. 31, 2023
Stockholders' Equity and Stock Based Compensation  
Stockholders' Equity and Stock Based Compensation

15.          Stockholders’ Equity and Stock Based Compensation:

The 2021 Omnibus Incentive Plan (the “2021 Plan”) authorizes the grant of Stock Options, Stock Units, Stock Appreciation Rights, Restricted Stock, Deferred Stock, Stock Bonuses and other equity-based awards. The 2021 Plan was approved by the Company’s stockholders at the 2021 Annual Meeting in June 2021. The total number of shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) initially available for award under the 2021 Plan was 500,000 shares. As of March 31, 2023, the number of shares of Common Stock available for future award grants to employees, officers and directors under the 2021 Plan is 329,770.

The 2012 Stock-Based Compensation Plan (the “2012 Plan”) authorizes the grant of Stock Options, Stock Units, Stock Appreciation Rights, Restricted Stock, Deferred Stock, Stock Bonuses and other equity-based awards. The total number of shares of the Company’s Common Stock initially available for award under the 2012 Plan was 600,000, which was increased to 1,000,000 shares by stockholder approval at the Company’s 2018 Annual Meeting in June 2018. Immediately prior to the replacement of the 2012 Plan by the 2021 Plan, there were 352,158 shares of Common Stock

available under the 2012 Plan. The 2012 Plan has been replaced by the 2021 Plan and none of the remaining shares of Common Stock authorized under the 2012 Plan will be transferred to or used under the 2021 Plan nor will any awards under the 2012 Plan that are forfeited increase the shares available for awards under the 2021 Plan. As of March 31, 2023, the number of shares of Common Stock available under the 2012 Plan was zero.

During the three months ended March 31, 2023, the Company granted a total of 43,824 shares of Restricted Stock to officers and employees. These shares of Restricted Stock vest over time in sixteen equal quarterly installments.

During the three months ended March 31, 2022, the Company granted a total of 30,999 shares of Restricted Stock to officers. These shares of Restricted Stock vest over time in sixteen equal quarterly installments. During the three months ended March 31, 2022, a total of 1,500 shares of Restricted Stock were forfeited.

A summary of nonvested shares of Restricted Stock awards outstanding under the 2012 and 2021 Plans as of March 31, 2023, and changes during the three months then ended is as follows:

Weighted

 

Average Grant

Date

 

Shares

Fair Value

 

Nonvested shares at January 1, 2023

 

121,059

$

24.83

Granted in 2023

 

43,824

 

39.75

Vested in 2023

 

(17,667)

 

24.23

Forfeited in 2023

 

 

Nonvested shares at March 31, 2023

 

147,216

$

29.34

As of March 31, 2023, there is approximately $3.8 million of total unrecognized compensation costs related to nonvested share-based compensation arrangements. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.4 years.

During the three months ended March 31, 2023 and 2022, the Company recognized share-based compensation expense of $0.5 million and $0.4 million, respectively.